ResearcherMoffitt Cancer CenterActive in the last 2 years
Patrick Hwu
Matched on ORCID iD 0000-0002-8293-1313; OpenAlex author ID A5033798832. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 32
2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers
Papers 6
- Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.111085↗
- Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2023-006822↗
- 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-0831↗
- Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep35848↗
- Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. Co-author DOI 10.1186/1756-8722-5-15↗
- Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-11-0607↗
Closest collaborators
The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ying Ma · 3 shared papers, 2011–2024 · strength 0.28
- Paper Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer. DOI 10.1016/j.isci.2024.111085↗
- Paper Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. DOI 10.1186/1756-8722-5-15↗
- Paper Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. DOI 10.1158/1078-0432.ccr-11-0607↗
- Baoan Ji · 3 shared papers, 2011–2024 · strength 0.28
- Paper Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer. DOI 10.1016/j.isci.2024.111085↗
- Paper Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. DOI 10.1186/1756-8722-5-15↗
- Paper Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. DOI 10.1158/1078-0432.ccr-11-0607↗
- Craig D. Logsdon · 3 shared papers, 2011–2024 · strength 0.28
- Paper Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer. DOI 10.1016/j.isci.2024.111085↗
- Paper Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. DOI 10.1186/1756-8722-5-15↗
- Paper Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. DOI 10.1158/1078-0432.ccr-11-0607↗
- Huamin Wang · 1 shared paper, 2024 · strength 0.22
- Xiangqin Zhao · 1 shared paper, 2024 · strength 0.22
- Michael James Overman · 2 shared papers, 2017–2024 · strength 0.21
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Milind M. Javle · 2 shared papers, 2017–2024 · strength 0.21
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Chantale Bernatchez · 2 shared papers, 2017–2024 · strength 0.21
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Donastas Sakellariou-Thompson · 2 shared papers, 2017–2024 · strength 0.21
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Rodabe Navroze Amaria · 1 shared paper, 2024 · strength 0.16
- Robert A. Wolff · 1 shared paper, 2024 · strength 0.16
- Amir Anthony Jazaeri · 1 shared paper, 2024 · strength 0.16
- Scott Kopetz · 1 shared paper, 2024 · strength 0.16
- Ying Yuan · 1 shared paper, 2024 · strength 0.16
- Shubham Pant · 1 shared paper, 2024 · strength 0.16
- Ching-Wei David Tzeng · 1 shared paper, 2024 · strength 0.16
- Anirban Maitra · 2 shared papers, 2016–2017 · strength 0.10
- Hector A. Alvarez · 2 shared papers, 2016–2017 · strength 0.10
- David Z. Chang · 2 shared papers, 2011–2012 · strength 0.06
- James L. Abbruzzese · 2 shared papers, 2011–2012 · strength 0.06
- Huamin Wang · 2 shared papers, 2011–2012 · strength 0.06
- Gauri A Varadhachary · 1 shared paper, 2017 · strength 0.05
- Jianhua Zhang · 1 shared paper, 2017 · strength 0.05
- Ya’an Kang · 1 shared paper, 2017 · strength 0.05
- Timothy Paul Heffernan · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.